1Lang P,Pardon A,Audard V.Long-term benefit of mycophenolate mofetil in renal transplantation[J].Transplan-tation,2005,79(3 Suppl):S47-S48.
2Bolwell B,Sobecks R,Pohlman B,et al.A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation[J].Bone Marrow Transplant,2004,34(7):621-625.
3Thervet E,Anglicheau D,Legendre C.Pharmacology of mycophenolate mofetil:recent data and clinical consequences[J].Nephrologie,2001,22(7):331-337.
5Shimon K, Rafael M. Infectious complications [ A ]//Shapiro R, Simmons RL, Starzl TE, ed.Renal transplantation [M]. Stanford: Appleton & Lange,1997: 315- 332.
6Rubin RH. The impact of infectious on the outcome of transplantation [J]. Transplant Proc. 1991,23(4):2 068 - 2 074.
7Sarmiento JM, Dockrell DH, Schwad TR, et al. Mycophenolate mofetil increases cytomegalovirus invasion organ disease in renal transplant patients [ J ]. Clin Transplant, 2000, 14(2) : 136- 138.
8Meulen CG, Wetzels JF, Hubrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation [J]. Nephrol Dial Transplant, 2000, 15: 711 - 714.
